Pomerantz Law Firm Launches Investigation of Oculis Holding AG Amid Securities Fraud Allegations

Pomerantz Law Firm Investigates Oculis Holding AG

On June 18, 2026, the Pomerantz Law Firm announced an investigation focused on potential claims involving investors of Oculis Holding AG, a company listed on NASDAQ under the ticker OCS. This inquiry stems from serious allegations regarding possible securities fraud and other unlawful business practices linked to the company and its directors.

The investigation follows a troubling announcement from Oculis on May 29, 2026. The company disclosed that two late-stage clinical trials, critical to the advancement of its lead candidate, OCS-01, for the treatment of diabetic macular edema, had failed to achieve their main objectives. The results indicated that both the Phase 3 DIAMOND-1 and DIAMOND-2 trials did not meet the expected endpoints, raising questions about the company's performance and management decisions.

In response to this shocking news, Oculis's stock plummeted by $6.95, a staggering 23.44% decrease, closing at $22.70 per share on the same day. This substantial drop has left many investors concerned about the integrity of the information provided by the company prior to these trials.

As the investigation unfolds, Pomerantz Law Firm is urging any investors affected to get in touch with their team for possible participation in a class action lawsuit. Interested parties can contact Danielle Peyton at [email protected] or by telephone at 646-581-9980, extension 7980. The firm is recognized for its commitment to advocating for the rights of investors, having secured numerous multi-million dollar damages awards in similar cases.

Founded over 85 years ago by the esteemed Abraham L. Pomerantz, who is often regarded as the father of securities class actions, the firm has a legacy of fighting against securities fraud. With offices located in major cities such as New York, Chicago, London, and Tel Aviv, Pomerantz continues to be a leader in corporate, securities, and antitrust litigation.

The current situation surrounding Oculis reflects broader challenges faced by medical firms in the ever-competitive biotech landscape, particularly regarding the reliability of clinical trial results. Investors are advised to stay updated on the evolving situation as it may influence the future viability of Oculis Holding AG.

Given the potential legal implications and the importance of investor protection, the Pomerantz Law Firm's investigation emphasizes the need for transparency and accountability in the healthcare sector. As the legal landscape adjusts to these developments, the firm remains dedicated to ensuring justice for investors who may be victims of corporate misconduct.

If you are an investor in Oculis Holding AG and would like to learn more about your rights, do not hesitate to reach out to the Pomerantz Law Firm for information on how to proceed.

Note: This article serves as a general update on the investigation status and does not guarantee any specific outcomes for involved parties.